Neurodegeneration and Neuroinflammation in Diabetic Retinopathy: Potential Approaches to Delay Neuronal Loss

Joanna Kadłubowska\textsuperscript{a}, Lucia Malaguarnera\textsuperscript{b}, Piotr Wąž\textsuperscript{c} and Katarzyna Zorena\textsuperscript{a,*}

\textsuperscript{a}Department of Immunobiology and Environment Microbiology, Medical University of Gdańsk, Gdańsk, Poland; \textsuperscript{b}Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy; \textsuperscript{c}Department of Nuclear Medicine, Medical University of Gdańsk, Gdańsk, Poland

Abstract: In spite of the extensive research the complex pathogenesis of diabetic retinopathy (DR) has not been fully elucidated. For many years it has been thought that diabetic retinopathy manifests only with microangiopathic lesions, which are totally responsible for the loss of vision in diabetic patients. In view of the current knowledge on the microangiopathic changes in the fundus of the eye, diabetic retinopathy is perceived as a neurodegenerative disease. Several clinical tools are available to detect neuronal dysfunction at early stages of diabetes. Many functional changes in the retina can be identified before vascular pathology develops, suggesting that they result from a direct effect of diabetes on the neural retina. In the course of diabetes there is a chronic loss of retinal neurons due to increased frequency of apoptosis. The neuronal apoptosis begins very early in the course of diabetes. This observation has led to suggestions that precautions against DR should be implemented immediately after diabetes is diagnosed. Neurodegeneration cannot be reversed; therefore treatments preventing neuronal cell loss in the retina need to be developed to protect diabetic patients. This review is an attempt to summarize what is currently known about the mechanisms of neuronal apoptosis in the context of diabetic retinopathy and vascular degeneration as well as about potential treatments of DR.

Keywords: Diabetic retinopathy, neurodegeneration of neurons, neuroinflammation, neuroprotection.

1. INTRODUCTION

As reported by the World Health Organization (WHO) currently there are 387 million people worldwide suffering from diabetes, which makes 8.3% of the global human population. By 2030 the number of people with diabetes is estimated to increase by 205 million, with a high percentage of them suffering from type 2 diabetes mellitus (T2DM) [1, 2]. Although clinically it is difficult to overlook type 1 diabetes mellitus (T1DM), many patients with T2DM, which is a slowly progressing disease, are unaware of their condition. It has been shown that in approximately 46% of patients at high risk of diabetes the disease remains undiagnosed. T2DM most commonly affects people aged 40 to 69 years, but over the last decades there has been more and more individuals who suffer from the disease before they are 40 [3-6]. Untreated or poorly controlled diabetes can increase the risk of serious complications, the therapy of which is a great burden to healthcare systems all over the world. The currently available long-term multidisciplinary studies have shown that long-term diabetic complications develop as a result of progressing vascular damage both in small and large blood vessels [7-9].

One of the major complications in patients with diabetes is diabetic retinopathy (DR), a leading cause of blindness worldwide. In spite of the extensive research the complex pathogenesis of diabetic retinopathy has not been fully elucidated [10-15]. For many years it has been thought that DR manifests only with microangiopathic lesions, which are totally responsible for the loss of vision in diabetic patients. In view of the current knowledge on the microangiopathic changes in the fundus of the eye, diabetic retinopathy is perceived as a neurodegenerative disease [13-15]. A large number of cellular and molecular studies in experimental animals and early retinal function tests in DR patients have shown that neurons are vulnerable to damage shortly after onset of diabetes [10, 11, 13, 14]. Several clinical tools such as optical coherence tomography (OCT), multifocal electroretinogram (mfERG), flash ERG, and short-wavelength automated perimetry have shown functional deficit in the
Multifocal ERG programs measure electrical activity from more than a hundred retinal areas per eye, in a few minutes. Through the use of mfERG Semeran et al. has provided evidence suggesting a direct link between neural dysfunction and vascular abnormalities in DR. In this regard, it has been shown that a delayed mfERG implicit time predicts the development of early microvascular abnormalities [17]. A good example is the comparison of mfERGs results to OCT measurements in order to correlate functional mfERG to morphological (CT) change. Early functional changes in the diabetic retina seem to occur before morphological changes in the retinal nerve fiber layer (RNFL) [18].

2. RETINAL NEURODEGENERATION IN THE COURSE OF DIABETES

Retinal neurodegenerative changes underlying the vision impairment in people with diabetes may develop as a result of genetic, chronic inflammation and metabolic disorders.

2.1. Hyperglycaemia and Changes in the Fundus of the Eye

Toxic effects of chronically elevated blood glucose levels include damage to pericytes in the retina of the eye. These cells are the first ones to be affected by changes induced by excess glucose supply [19, 20].

Harmful effects in the pericytes are mediated by activation of several metabolic pathways including nonenzymatic glycation of proteins, which is among the most important biochemical processes playing a key role in the development of angiopathic complications in diabetes. This process results in formation of advanced glycation endproducts (AGEs), which are long-lasting and irreversible products that have the ability to form cross-links between proteins with subsequent modification of blood vessel elasticity [21-24].

In animal studies stimulation of inflammatory response by receptor for the advanced glycation end products (RAGEs) induced mononuclear phagocytes was observed. Moreover in the acute peripheral nerve injury the ligand-RAGE complex can modulate inflammatory response and neurite outgrowth. In subjects suffering from diabetes there is increased synthesis of RAGEs in macrophages and monocytes migrating from the circulation into the tissues. Increased expression of the receptors on the endothelium and smooth muscle cells was observed and shown to be stimulated by increased AGE levels, which resulted in long-term angiopathic complications. This phenomenon was observed in diabetic retinopathy [25-27]. In retinal capillaries of patients with advanced diabetes the endothelial AGE-RAGE complexes stimulated nuclear factor xB (NF-xB) transcription factor. This resulted in increased vascular endothelial growth factor (VEGF) synthesis and leukocyte adhesion to these cells as well as potentiated inflammatory response [27, 28]. Currently available studies revealed AGEs and sRAGE threshold values for the risk of development of retinopathy and nephropathy in children and adolescents with type 1 diabetes Fig. 1a,b [29].

2.2. Oxidative Stress

The polyol pathway, nonenzymatic glycation of proteins with its endproducts, protein kinase C activation and hexosamine pathway lead to a series of pathological events including increased production of free oxygen radicals, oxidative stress, activation of proangiogenic factors and finally inflammation [30-39]. Hyperglycaemia, due to enhanced production of superoxide anion radicals by electron transport chain in mitochondria triggers a self-perpetuating cycle of production of oxygen free radicals [32-34]. Oxygen free radicals including peroxide anion radical and hydroxyl radical are a part of a whole body of reactive oxygen species (ROS). Peroxide anion radical is generated in mitochondria by electron transport chain in oxidative phosphorylation reaction as a product of non-enzymatic one-electron reaction with oxygen. However the peroxide anion radical is not able to pass cell membranes, remains within the membranes and is deactivated by superoxide dismutase. The reaction results in hydrogen peroxide which can diffuse from mitochondria and transform into highly reactive hydroxyl radical [35-37]. In all types of cells with possible hyperglycaemia free oxygen radicals cause a decrease in activity of the key glycolytic enzyme glyceraldehyde 3-phosphate dehydrogenase (GAPDH) [35]. GAPDH is an essential enzyme in the process of glycolysis. Decreased activity of GAPDH results in increased levels of the reaction substrates and intermediate products. Overexpression of glyceraldehyde 3-phosphate dehydrogenase prevents neurovascular degeneration after retinal injury [35]. Moreover oxygen free radicals can increase vascular permeability and reduce the ability of blood vessels to dilate as well as can activate growth factors and platelets resulting in vasoconstriction following endothelial injury [36]. Oxidative stress which is a consequence of prolonged hyperglycaemia is a key link in connecting angiopathic complications in the course of diabetes [30, 31, 40]. It has been shown that oxidative stress is associated with impairment in neuroretinal biochemical homeostasis in patients with PDR, which further augments retinal nitrosative stress and thus worsens the pathogenic process of retinopathy among patients with PDR [40].

2.3. Glutamate Excitotoxicity and Retinal Ganglion Cell Death

In the course of diabetes high blood glucose leads to neuron vulnerability and apoptosis through many mechanisms, with recently explored pathways illustrated in Fig. 2. Glutamate excitotoxicity is indicated as one of the mechanisms that can lead to oxidative stress mediated retinal ganglion cell death in diabetes [41-44]. At physiological conditions the
proteolytic enzymes, and finally leads to DNA fragmentation. The cascade of activation of further caspases, which are complexes with apoptotic protease-activating factor-1 (AIF) and cytochrome c [48]. The membrane potential and initiate leakage of apoptosis. Pro-apoptotic proteins reduce mitochondrial Hik, Bak) and anti-apoptotic proteins Bcl-2, Bcl-x, A-1, and neuron death [47, 53, 54]. Currently available data suggest that the main mechanism underlying the induction of neuron apoptosis under chronic excitotoxic conditions is the mitochondrial apoptosis pathway rather than Fas signalling pathway [48, 53]. Caspases, the enzymes involved in apoptosis are also elevated in retinas of diabetic rats thus making them markers for apoptosis [55-57]. The role of pro-inflammatory cytokine (IL-1) and caspase-1 in diabetes-induced mice has shown that caspase-1/IL-1 signalling pathways play an important role in degeneration of retinal capillaries and its inhibition might represent a new strategy to inhibit capillary degeneration in diabetic retinopathy [55]. The increased expression of anti-apoptotic mediator Bcl-2 in the vascular endothelium inhibits the diabetes-induced degeneration of retinal capillaries and superoxide generation [57].

Tumor necrosis factor-α (TNF-α) has a contradictory effect on cells, it may promote cell survival or death, depending on the presence of other molecules. In the ganglion neurons of a healthy human retina normal levels of TNF-α stimulate the activity and expression only of the pro-survival molecules, for example Cox-2 and Akt, but the diabetic retina expressed also molecules involved in the pro-apoptotic pathways: release of mitochondrial cytochrome c, AIF (apoptosis inducing factor), Bad [52]. In cultured retinal neurons TNF-α works primarily through the TNFR-1 and initiates apoptosis via the caspase system [58]. Aside from the caspases, MKK/JNK/Jun pathway is activated in the apoptotic neurons of retinas of humans and rats, ERK/Fos in human retina and Bax system in rat retina [59, 60].

The proposed mechanisms for the role of high glucose concentrations on the cells of the retina are illustrated in Fig. 2.
3. NEUROINFLAMMATION IN THE COURSE OF DIABETES

In the numerous studies on the pathogenesis of diabetic retinopathy more and more attention is paid to inflammatory and angiogenic factors [7, 8, 61-63]. The development and progression of diabetic retinopathy may result on one hand from stimulation of immune cells in metabolically uncontrolled disease and on the other hand from the presence of proinflammatory cytokines, which reflects the ongoing...
immune processes initiated already in the phase of prediabetes. Animal studies have shown that as early as after one week of diabetes, before any signs of diabetic retinopathy occur, leukocytes start to adhere to the retinal capillaries with subsequent migration into the retina. Leukocyte-endothelial cell adherence is regulated by integrins expressed on the surface of leukocytes as lymphocyte function-associated antigen-1 (LFA-1), very late activation antigen-4 (VLA-4), CD18 and adhesion molecules expressed on the surface of endothelial cells including intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), P-selectins [64, 65]. The leukocyte-endothelial adhesion initiates the process of releasing proinflammatory cytokines, growth factors and vascular permeability factors. Furthermore endothelial tight junctions are being damaged, which facilitates leukocyte diapedesis to the retina [65, 66]. Moreover currently available studies have shown increased serum levels of proinflammatory cytokines in adolescents with T1DM and diabetic retinopathy [17, 29, 66]. Also increased serum interleukin-6 (IL-6) levels were detected in patients with proliferative diabetic retinopathy (PDR) versus patients with T1DM but without PDR [7, 64]. Markedly increased expression of IL-6 and VEGF was found in the aqueous humour of patients with diabetic macular oedema. Other studies have shown a positive correlation between the aqueous levels of IL-6 and macular thickness, which indicates that IL-6 may play a role in the development of diabetic macular oedema [67]. Higher levels of high-mobility group box-1 protein (HMGB1), VEGF, ICAM-1, VCAM-1, soluble vascular endothelial-cadherin (sVE-cadherin), vascular adhesion protein (VAP-1), erythropoietin (EPO), and chemokines have been recently reported in vitreous fluid from PDR patients compared to nondiabetic patients [68-71]. It is speculated that HMGB1 might be an important link between chronic low-grade inflammation and angiogenesis. HMGB1 functions as a proinflammatory cytokine and exhibits angiogenic effects [68].

Study results from the last years suggest that genetically determined higher production of cytokines may significantly affect the onset and progression of diabetic retinopathy [70-73]. So far, several candidate genes have been implicated in the pathogenesis of diabetic retinopathy via complex interactions of environmental and genetic factors. None of them, however, can be fully and solely responsible for the development of DR. Expression of growth factors, such as VEGF, basic fibroblast growth factor (BFGF), and insulin-like growth factor (IGF), is influenced by single-nucleotide polymorphisms (SNPs) in these genes [74-76].

Furthermore, on the basis of the data published so far we can assume that the development of diabetic retinopathy can be affected by VEGF and increased blood pressure [77, 78]. Persistent elevated HbA1c levels is known to lead to the production and accumulation of AGES. Formation of AGES promotes production of pro-inflammatory cytokines, which may further increase VEGF levels and thus indirectly lead to the increased blood pressure. This process results in increased expression of adhesion molecules, cytokines and chemokines that enhance endothelial cell proliferation and extracellular matrix formation with concomitant impairment of its degradation. The consequence of these actions is progressive fibrosis and obliteration of the vascular lumen resulting in increased vascular resistance in these vessels. Increased blood flow resistance leads to further increase in VEGF production and potentiates changes in the structure and proportions of collagen and elastin, thereby leading to increased stiffness of blood vessels and progressing hypertension. Dyslipidemia, smoking and lack of physical activity are among the well-established clinical risk factors for the development and progression of diabetic retinopathy however they are beyond the scope of this article [79-81].

4. POTENTIAL APPROACHES TO DELAY NEURONAL LOSS IN THE COURSE OF DIABETES

Neurodegeneration cannot be reversed, therefore preventing neuronal cell loss in the retina need to be developed to protect diabetic patients [14, 82]. During the last years several interventions with possible neuroprotective effects have been investigated, mostly in rats and mice. The effect of exercise on retinal neurons was investigated on the example of rats running on a treadmill. The physical exercise altered the risk of developing diabetic retinopathy: the number of apoptotic cells in the retina was reduced [83] and the level of VEGF was lowered [84].

In another study by Marchetti et al. umbilical cord blood (UCB) derived CD14+ cells were introduced intravitreally into C57Bl/6J mice with oxygen-induced retinopathy [85]. In this model seven-days-old mice are kept in 75% oxygen atmosphere for five days and returned to normal atmosphere. Elevated oxygen concentrations cause the retinal vasculature to degenerate. Under normal atmosphere tissues with degenerated vasculature become hypoxic and are used as a model of hypoxic injury to the retina. At the interface between perfused and non-perfused retina abnormal lesions develop including pre-laminar, neovascular tufts in C57Bl/6J mice. BALB/cByJ mice revascularize more quickly and develop normal vasculature, which makes them a good control in studies of recovery from hypoxic injury. Human UCB-derived CD14+ cells caused that hypoxic injury in the C57Bl/6J retina healed similarly to the BALB/cByJ retina, while CD14- cells offered only modest improvement. Human CD14+ cells were found around the vasculature and matured into macrophage-like morphology. Their antigens were consistent with those of M2 type macrophages. Moreover human UCB-derived CD14+ cells were matured in vitro into M1 and M2 macrophages and subsequently introduced intravitreally to C57Bl/6J mice with oxygen-induced retinopathy. Both populations were able to protect retinal vasculature against obliteration, however only M2 macrophages prevented formation of neovascular tufts. In transcriptomic analysis human cells showed increased expression of proteins associated with response to oxidative stress (e.g. SOD1, HMOX1, GPX1, ALDOA), anti-inflammatory proteins (Stat3, CCR5, TIMP1), proteins promoting cell survival over apoptosis (e.g. TGF-β, AKT1, NF-kB) and myeloid differentiation, while pro-inflammatory TNF-α was downregulated.

Several diabetes drugs were found to protect retinal neurons against apoptosis. The main effect of rosiglitazone involves sensitization of cells to insulin, therefore its effect
on retinal neurons' survival is most likely indirect. Rosiglitazone has been shown to provide anti-apoptotic protection for all layers of retinal neurons [86-90]. The recent years have brought new evidence on rosiglitazone that have changed its position. The medicine has been shown to elevate the risks of myocardial infarction and cardiovascular death [87]. As a result it has been withdrawn from the market in some countries while in the others its sale has considerably declined. Discovering new benefits from using the drug may not be enough to balance the risk of cardiovascular diseases.

Another drug with potential effect on retinal neurons is sitagliptin. Its main mode of action is inhibition of GLP-1 and GIP (gastrointestinal hormones) inactivation with subsequently prolonged insulin secretion after meals. Sitagliptin exerts different effects on diabetes control depending on the type of diabetes in animal models but both in type 1 and type 2 Zucker Diabetic Fatty (ZDF) rats it provides protection to the retinas. Its administration results in increased neuronal viability, tighter blood-retina barrier (BRB) integrity and lower level of inflammation [88-90].

Other drugs used in diabetes for reasons other than glycaemic control can also improve retinal health. Cilostazol is commonly used in management of diabetic complications and protects rat retinas against ischemia [91]. Acetylsalicylic acid alleviated microangiopathy in a process different from reducing inflammation and antithrombotic effect [92]. A nonpsychotropic cannabinoid, cannabidiol, reduced BRB breakdown, neuronal apoptosis and inflammation [93]. Propranolol can either reduce or intensify vascular changes depending on the model, but in animal in vivo experiments it caused mostly improved mediatied by reduction of VEGF overexpression. This effect in turn may raise neuronal apoptosis [94].

Herbal preparations that have been investigated in this setting include KIOM-79, Purendan superfine powder and Litsea japonica extract. KIOM-79 and Litsea japonica extract reduced AGE accumulation and in consequence improved neuronal viability; Purendan superfine powder altered cell survival signalling which resulted in lower number of apoptotic retinal ganglion cells [95-97].

5. CONCLUSION

In conclusion, neurodegeneration, as above mentioned, cannot be reversed and therefore new neuroprotective agents are expected to provide a new strategy of treatment for early stages of diabetic retinopathy. There is a growing need for clinical studies to evaluate the efficacy of noninvasive treatment approaches with neuroprotective drugs. The research on diabetic animal models that developed clinical manifestations of retinopathy is needed as they may provide a correlation of the systemic metabolic profiles and retinal pathology with human studies. In view of the complexity of diabetic retinopathy, it seems likely that combinatory therapy will be required with pathways targeting different cell types at different stages of the disease process. Hopefully in the nearest future neuroprotection will become an effective therapeutic option in the “armoury” against diabetic retinopathy.
Neurodegeneration and Neuroinflammation in Diabetic Retinopathy

Current Neuropharmacology, 2016, Vol. 14, No. 8 837

Barber, A.J. Diabetic retinopathy: recent advances towards understanding neurodegeneration and vision loss. Sci. China Life Sci., 2015, 58(6), 541-549. [http://dx.doi.org/10.1007/s11427-015-0485-x] [PMID: 25951929]

Jindal, V. Neurodegeneration as a primary change and role of neuroprotection in diabetic retinopathy. Mol. Neurobiol., 2015, 51(3), 878-884. [http://dx.doi.org/10.1007/s12035-014-8732-7] [PMID: 24826918]

Ola, M.S.; Alhomida, A.S. Neurodegeneration in diabetic retina and its potential drug targets. Curr. Neuropharmacol., 2014, 12(4), 380-386. [http://dx.doi.org/10.2147/CNP.S42945] [PMID: 25342945]

Sutter, E.E. Noninvasive Testing Methods: Multifocal Electroretinography. In: Encyclopedia of the Eye; Durtt, D.A., Ed.; Academic Press: Oxford, 2010, Vol. 3, pp. 142-160. [http://dx.doi.org/10.1016/B978-0-12-374203-2.00226-8] [PMID: 19905302]

Semera, K.; Pawłowski, P.; Lisowski, Ł.; Szczepaniak, I.; Bharadwaj, A.S.; Appukuttan, B.; Wilmarth, P.A.; Pan, Y.; Mancini, J.E.; Ortiz, G.; Croxatto, J.O.; Gallo, J.E. Retinal cell in ocular disease. Proc. Natl. Acad. Sci., 2009, 106(12), 13-14. [http://dx.doi.org/10.1073/pnas.0801804106] [PMID: 19322705]

Beisswenger, PJ. Glycation and biomarkers of vascular complications of diabetes. Amino Acids, 2012, 42(4), 1171-1183. [http://dx.doi.org/10.1007/s00726-010-0784-z] [PMID: 21042818]

Yan, S.F.; Yan, S.D.; Ramsamy, R.; Schmidt, A.M. Temppering the wrath of RAGE: an emerging therapeutic strategy against diabetic complications, neurodegeneration, and inflammation. Ann. Med., 2009, 41(6), 408-422. [http://dx.doi.org/10.1080/07853900902806576] [PMID: 19322705]

Bharadwaj, A.S.; Appukuttan, B.; Wilmarth, P.A.; Pan, Y.; Siempel, A.J.; Chips, T.J.; Benedetti, E.E.; Zamora, D.O.; Choi, D.; David, L.L.; Smith, J.R. Role of the retinal vascular endothelial cell in ocular disease. Prog. Retin. Eye Res., 2013, 32, 102-180. [http://dx.doi.org/10.1016/j.preteyeres.2012.08.004] [PMID: 22982179]

Fu, S.; Dong, S.; Zhu, M.; Sherry, D.M.; Wang, C.; You, Z.; Haigh, J.J.; Le, Y.Z. Müller glia are a major cellular source of survival signals for retinal neurons in diabetes. Diabetes, 2015, 64(10), 3554-3563. [Epub ahead of print]. [http://dx.doi.org/10.2337/db15-0180] [PMID: 26086851]

Zorena, K.; Kula, M.; Malinowska, E.; Raczyńska, D.; Myśliwiec, M.; Raczyńska, K. Threshold serum concentrations of tumor necrosis factor alpha (TNFα) as a potential marker of the presence of the disease microangiopathy in children and adolescents with type 1 diabetes mellitus (T1DM). Hum. Immunol., 2013, 74(1), 75-81. [http://dx.doi.org/10.1016/j.humimm.2012.10.002] [PMID: 23073299]

Giacco, F.; Brownlee, M. Oxidative stress and diabetic complications. Circ. Res., 2010, 107(9), 1058-1070. [http://dx.doi.org/10.1161/CIRCRESAHA.110.222545] [PMID: 21030723]

Kowluž, R.A.; Chan, P.S. Oxidative stress and diabetic retinopathy. Exp. Diabetes Res., 2007, 2007, 43603. [http://dx.doi.org/10.1155/2007/43603] [PMID: 17641741]

Zhang, L.; Yu, C.; Vasquez, F.E.; Galeva, N.; Onyango, I.; Swerdlov, R.H.; Dobrowsky, R.T. Hyperglycemia alters the schwann cell mitochondrial proteome and decreases respiratory activity in the presence of superoxide production. J. Proteome Res., 2010, 9(1), 458-471. [http://dx.doi.org/10.1021/pr900818g] [PMID: 20339156]

Aghdam, S.Y.; Gurel, Z.; Ghaffarieh, A.; Sorenson, C.M.; Sheibani, N. High glucose and diabetes modulate cellular proteasome function: Implications in the pathogenesis of diabetes complications. Biochem. Biophys. Res. Commun., 2013, 432(2), 339-344. [http://dx.doi.org/10.1016/j.bbrc.2013.01.011] [PMID: 23391566]

Hammes, H.P. Pericytes and the pathogenesis of diabetic retinopathy. Horiz. Metab. Res., 2005, 37(Suppl. 1), 39-43. [http://dx.doi.org/10.1055/s-2005-86316] [PMID: 15918109]

Simó, R.; Hernández, C. Neurodegeneration is an early event in diabetic retinopathy: therapeutic implications. Br. J. Ophthalmol., 2012, 96(10), 1285-1290. [http://dx.doi.org/10.1136/bjophthalmol-2012-302005] [PMID: 22887976]

Zorena, K.; Raczyńska, D.; Raczyńska, K. Biomarkers in diabetic retinopathy and the therapeutic implications. Mediators Inflamm., 2013, 2013, 193604. [http://dx.doi.org/10.1155/2013/193604] [PMID: 24311895]

Muñoz, J.E.; Ortiz, G.; Croxatto, J.O.; Gallo, J.E. Retinal upregulation of inflammatory and proangiogenic markers in a model of neonatal diabetic rats fed on a high-fat-diet. BMC Ophthalmol., 2013, 13, 14. [http://dx.doi.org/10.1186/1471-2415-13-14] [PMID: 23587252]

Yamagishi, S.; Matsui, T. Soluble form of a receptor for advanced glycation end products (sRAGE) as a biomarker. Front. Biosci. (Elite Ed.), 2010, 2, 1184-1195. [http://dx.doi.org/10.2741/e179] [PMID: 20515790]

Beisswenger, PJ. Glycation and biomarkers of vascular complications of diabetes. Amino Acids, 2012, 42(4), 1171-1183. [http://dx.doi.org/10.1007/s00726-010-0784-z] [PMID: 21042818]

Yan, S.F.; Yan, S.D.; Ramsamy, R.; Schmidt, A.M. Temppering the wrath of RAGE: an emerging therapeutic strategy against diabetic complications, neurodegeneration, and inflammation. Ann. Med., 2009, 41(6), 408-422. [http://dx.doi.org/10.1080/07853900902806576] [PMID: 19322705]

Bharadwaj, A.S.; Appukuttan, B.; Wilmarth, P.A.; Pan, Y.; Siempel, A.J.; Chips, T.J.; Benedetti, E.E.; Zamora, D.O.; Choi, D.; David, L.L.; Smith, J.R. Role of the retinal vascular endothelial cell in ocular disease. Prog. Retin. Eye Res., 2013, 32, 102-180. [http://dx.doi.org/10.1016/j.preteyeres.2012.08.004] [PMID: 22982179]

Fu, S.; Dong, S.; Zhu, M.; Sherry, D.M.; Wang, C.; You, Z.; Haigh, J.J.; Le, Y.Z. Müller glia are a major cellular source of survival signals for retinal neurons in diabetes. Diabetes, 2015, 64(10), 3554-3563. [Epub ahead of print]. [http://dx.doi.org/10.2337/db15-0180] [PMID: 26086851]
retina in streptozotocin-induced diabetic rats. CNS Neurosci. Ther., 2013, 19(12), 945-953. [http://dx.doi.org/10.1111/cns.12150] [PMID: 23870489]

Al-Shabrawey, M.; Smith, S. Prediction of diabetic retinopathy: role of oxidative stress and relevance of apoptotic biomarkers. EPMA J., 2010, 1(1), 56-72. [http://dx.doi.org/10.1007/s13167-010-0002-9] [PMID: 21399041]

Potheccary, C.A.; Thompson, H.; Salt, T.E. Changes in glutamate receptor function in synaptic input to the superficial superior colliculus (SSC) with aging and in retinal degeneration in the Royal College of Surgeons (RCS) rat. Neurobiol. Aging, 2005, 26(6), 960-972. [http://dx.doi.org/10.1016/j.neurobiolaging.2004.07.004] [PMID: 15718056]

Kannan, K.; Jain, S.K. Oxidative stress and apoptosis. Pathophysiology, 2000, 7(3), 153-163. [http://dx.doi.org/10.1076/1098-4680(20000300)7:3<153::AID-PATH527>3.0.CO;2-8] [PMID: 10996650]

Nogueira, T.C.; Paula, F.M.; Villate, O.; Colli, M.L.; Moura, R.F.; Valverde, A.M.; Miranda, S.; García-Ramírez, M.; González-Juarranz, M.; Abu El-Asrar, A.M.; Dralands, L.; Missotten, L.; Geboes, K.; Kern, T.S.; Du, Y.; Miller, C.M.; Hatala, D.A.; Levin, L.A.; Ortis, F.; Cardozo, A.K.; Crispim, D.; Störling, J.; Mandrup-Poulsen, T.; Eizirik, D.L. GLIS3, a susceptibility gene for type 1 and type 2 diabetes, modulates pancreatic beta cell apoptosis via regulation of a splice variant of the B3-only protein Bim. PLoS Genet., 2013, 9(5), e1003532. [http://dx.doi.org/10.1371/journal.pgen.1003532] [PMID: 23737756]

Khaltaoui, T.; Basora, N.; Ouerhani-Meddibe, A. Apoptotic factors (Bax and Bcl-2) and diabetic retinopathy in type 2 diabetes. J. Mol. Histol., 2010, 41(2-3), 143-152. [http://dx.doi.org/10.1007/s10735-010-9271-9] [PMID: 20532811]

Rogowicz-Frontczak, A.; Pilaciński, S.; Araszkiewicz, A.; Zuzolina-Ziolkiewicz, D.; Wykretowicz, A.; Wierusz-Wysoka, E. Reactive protein and soluble intracellular adhesion molecule-1 are related to pulse wave reflection in type 1 diabetes IC-1. J. Diabetes, 2014, 6(6), 577-585. [http://dx.doi.org/10.10111/j.1753-0407.12129] [PMID: 24456306]

Yu, Y.; Chen, H.; Su, S.B. Neuroinflammatory responses in diabetic retinopathy. J. Neuroinflammation, 2015, 12, 141. [http://dx.doi.org/10.1186/s12974-015-0368-7] [PMID: 26254688]

Abouer, S.F.; Gardner, T.W. Diabetic retinopathy: loss of neuroretinal adaptation to the diabetic metabolic environment. Ann. N. Y. Acad. Sci., 2014, 1311, 174-190. [http://dx.doi.org/10.1111/nyas.12412] [PMID: 24673341]

Crane, I.J.; Liversidge, J. Mechanisms of leukocyte migration across the blood-retina barrier. Semin. Immunopathol., 2008, 30(2), 165-177. [http://dx.doi.org/10.1007/s00281-008-0106-7] [PMID: 18305941]

Caahoon, J.M.; Olson, P.R.; Nielson, S.; Miya, T.R.; Bankhead, P.; McGeeown, J.G.; Curtis, T.M.; Ambati, B.K. Acridine orange leukocyte fluorography in mice. Exp. Eye Res., 2014, 120, 15-19. [http://dx.doi.org/10.1016/j.exer.2013.12.002] [PMID: 24333760]

Stroka, K.; Ballondina, E.; Raczynska, D.; Myśliwiec, M.; Raczynska, K. Serum concentrations of transforming growth factor-Beta 1 in predicting the occurrence of diabetic retinopathy in juvenile patients with type 1 diabetes mellitus. J. Diabetes Res., 2013, 2013, 614908. [http://dx.doi.org/10.1155/2013/614908] [PMID: 23671881]

To, J.K.; Kim, S.W.; Oh, J.; Lee, T.S.; Huh, K. Inflammatory and angiogenic factors in the aqueous humor and the relationship to diabetic retinopathy. Curr. Eye Res., 2010, 35(12), 1116-1127. [http://dx.doi.org/10.3109/02713683.2010.510257] [PMID: 21121809]

Ambati, J.; Amawad, M.; Kivange, D.; Abouammoh, M.; Mohammed, G. High-mobility group box-1 and endothelial cell angiogenic markers in the vitreous from patients with proliferative diabetic retinopathy. Mediators of Inflammation, 2012, Article ID 697489, 7 pages, 2012 [http://dx.doi.org/10.1155/2012/697489]

Proietto, M.G.; Korošec, P.; Košnik, M.; Hawlin, M. Vitreous levels of interleukin-8 in patients with proliferative diabetic retinopathy. Am. J. Ophthalmol., 2007, 143(1), 175-176. [http://dx.doi.org/10.1016/j.ajo.2006.07.032] [PMID: 17188064]

Hernández, C.; Fonollosa, A.; García-Ramírez, M.; Higuera, M.; Catalán, R.; Miralles, A.; García-Arumí, J.; Simón, R. Erythropoietin is expressed in the human retina and it is highly elevated in the vitreous fluid of patients with diabetic macular edema. Diabetes Care, 2006, 29(9), 2028-2033. [http://dx.doi.org/10.23736/0026-0655(2006)046-153d] [PMID: 16936148]

Muzikant, M.; Hryzko, L.; Riesz, C.; Karlecker, M.; Langmann, T.; Dröge, K.; Caramoy, A.; den Hollander, A.L.; Fauser, S. Genetic and environmental risk factors for age-related macular degeneration in persons 90 years and older. Invest. Ophthalmol. Vis. Sci., 2014, 55(3), 1842-1847. [http://dx.doi.org/10.1167/iovs.13-13420] [PMID: 24576882]

Doria, A. Genetics of diabetes complications. Curr. Diab. Rep., 2010, 10(6), 467-475. [http://dx.doi.org/10.1007/s11892-010-0147-x] [PMID: 20835900]

Cilenšek, I.; Hercegovac, A.; Vukojevič, K.; Babić, M.S.; Milutinović Živin, A. Polymorphisms of interleukin-4, -10 and -30 genes in the human retina and it is highly elevated in the vitreous fluid of patients with diabetic macular edema. Diabetes Care, 2013, 36(5), 1635-1639. [http://dx.doi.org/10.23736/S0149-9200(13)30205-6] [PMID: 24010344]

Awata, T.; Inoue, K.; Kurihara, S.; Ohkubo, T.; Watanabe, M.; Inukai, K.; Inoue, I.; Karayama, S. A common polymorphism in the 5′-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes, 2002, 51(5), 1635-1639. [http://dx.doi.org/10.23737/diabetes.51.5.1635] [PMID: 11978667]

Choudhuri, S.; Chowdhury, I.H.; Das, S.; Dutta, D.; Saha, A.; Sarkar, R.; Mandal, L.K.; Mukherjee, S.; Bhattacharya, B. Role of NF-xB activation and VEGF gene polymorphisms in VEGF up regulation in non-proliferative and proliferative diabetic retinopathy. Curr. Eye Res., 2010, 35(8), 709-718. [http://dx.doi.org/10.3109/02713683.2010.510257] [PMID: 21121809]
Neurodegeneration and Neuroinflammation in Diabetic Retinopathy

Mol. Cell. Biochem., 2015, 405(1-2), 265-279. [http://dx.doi.org/10.1007/s10529-014-2417-z] [PMID: 25956512]

[77] Barengo, N.C.; Tuomilehto, J.O. Blood pressure treatment target in patients with diabetes mellitus--current evidence. Am. Med., 2012, 44(Suppl. 1), S36-S42. [http://dx.doi.org/10.3109/07853890.2012.679661] [PMID: 22713147]

[78] Izzo, R.; de Simone, G.; Trimarco, V.; Gerds, E.; Giudice, R.; Vaccaro, O.; De Luca, N.; Trimarco, B. Hypertensive target organ damage predicts incident diabetes mellitus. Eur. Heart J., 2013, 34(44), 3419-3426. [http://dx.doi.org/10.1093/eurheartj/eht281] [PMID: 23882068]

[79] Zorena, K.; Myśliwska, J.; Myśliwiec, M.; Rybarczyk-Kapturska, K.; Malinowska, E.; Wińciewski, P.; Raczyńska, K. Association between vascular endothelial growth factor and hypertension in children and adolescents type 1 diabetes mellitus. J. Hum. Hypertens., 2010, 24(11), 755-762. [http://dx.doi.org/10.1038/jhh.2010.7] [PMID: 20164848]

[80] Pons, M.; Marin-Castaño, M.E. Cigarette smoke-related hydroquinone dysregulates MCP-1, VEGF and PEDF expression in retinal pigmented epithelium in vitro and in vivo. PLoS One, 2011, 6(2), e16722. [http://dx.doi.org/10.1371/journal.pone.0016722] [PMID: 21386905]

[81] Ciszar, A.; Gautam, T.; Sosnowska, D.; Tarantini, S.; Banki, E.; Tusek, Z.; Toth, P.; Losonczy, G.; Koller, A.; Reglodi, D.; Giles, C.B.; Wren, J.D.; Sonntag, W.E.; Ungvari, Z. Caloric restriction confers persistent anti-oxidative, pro-angiogenic, and anti-inflammatory effects and promotes anti-aging miRNA expression profile in cerebrovascular endothelial cells of aged rats. Am. J. Physiol. Heart Circ. Physiol., 2014, 307(3), H292-H306. [http://dx.doi.org/10.1152/ajpheart.00307.2014] [PMID: 24906921]

[82] Ursu, A.; Araszkiewicz, A.; Ursu, P.; Zozulinska-Ziolkiewicz, D. Higher risk of microvascular complications in smokers with type 1 diabetes despite intensive insulin therapy. Microvasc. Res., 2014, 92, 79-84. [http://dx.doi.org/10.1016/j.mvr.2014.01.002] [PMID: 24423616]

[83] Li, P.; Xu, X.; Zheng, Z.; Zhu, B.; Shi, Y.; Liu, K. Protective effects of rosiglitazone on retinal neuronal damage in diabetic rats. Curr. Eye Res., 2011, 36(7), 673-679. [http://dx.doi.org/10.3109/02713683.2011.572220] [PMID: 21599458]

[84] Nissen, S.E.; Wolski, K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med., 2007, 356(24), 2457-2471. [http://dx.doi.org/10.1056/NEJMoa072761] [PMID: 17517853]

[85] El-Remessy, A.B.; Al-Shabrawey, M.; Khalifa, Y.; Tsai, N.T.; Casini, G.; Dal Monte, M.; Fornaciari, I.; Filippi, L.; Bagnoli, P. The β-adrenergic system as a possible new target for pharmacologic treatment of neurovascular retinal diseases. Prog. Retin. Eye Res., 2014, 42, 103-129. [http://dx.doi.org/10.1016/j.preteyeres.2014.06.001] [PMID: 24933041]

[86] Dong, Z.; Tao, X.; Fu, X.; Wang, H.; Wang, D.; Zhang, T. Protective effects of Puerarin superfine powder on retinal neuron apoptosis in a rat model of type 2 diabetes mellitus. Neuropharmacology, 2012, 73(3), 202-206. [PMID: 25767500]

[87] Kim, J.; Kim, C.S.; Lee, Y.M.; Sohn, E.; Jo, K.; Kim, J.S. Litsea japonica extract inhibits neuronal apoptosis and the accumulation of advanced glycation end products in the diabetic mouse retina. Mol. Med. Rep., 2015, 12(1), 1075-1081. [PMID: 25815519]